CD274 and neoplasm: In the early stages of our study, the application of chemotherapy or EGFR-TKIs for EGFR mutation patients was found to be an increase in the expression of PD-L1 in the tumor cell surface, and the PD-L1 was significantly reduced after the treatment of the anti-PD-1.